DrugPatentWatch Database Preview
Drugs in Development Information for ND0612
Email this page to a colleague
» See Plans and PricingWhat is the drug development status for ND0612?
ND0612 is an investigational drug.
There have been 9 clinical trials for ND0612.
The most recent clinical trial was a Phase 2 trial, which was initiated on August 1st 2016.
The most common disease conditions in clinical trials are Parkinson Disease and [disabled in preview]. The leading clinical trial sponsors are NeuroDerm Ltd., Quotient Clinical, and Michael J. Fox Foundation for Parkinson's Research.
There are twenty-three US patents protecting this investigational drug and one hundred and sixty-nine international patents.
Summary for ND0612
| US Patents | 23 |
| International Patents | 169 |
| US Patent Applications | 32 |
| WIPO Patent Applications | 58 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2016-08-01) |
| Vendors | 2 |
Recent Clinical Trials for ND0612
| Title | Sponsor | Phase |
|---|---|---|
| A Clinical Trial Investigating the Efficacy, Safety and Tolerability of Continuous Subcutaneous ND0612 Infusion in Comparison to Oral IR-LD/CD in Subjects With Parkinson's Disease Experiencing Motor Fluctuations (BouNDless). | NeuroDerm Ltd. | Phase 3 |
| A Clinical Study Investigating the Efficacy, Tolerability, and Safety of Continuous Subcutaneous ND0612 Infusion Given as Adjunct Treatment to Oral Levodopa in Patients With Parkinson's Disease With Motor Fluctuations | NeuroDerm Ltd. | Phase 3 |
| A Clinical Study Investigating Long Term Safety of ND0612, a Solution of Levodopa/Carbidopa Administered as a Continuous Subcutaneous Infusion in Subjects With Advanced Parkinson's Disease | NeuroDerm Ltd. | Phase 2 |
Clinical Trial Summary for ND0612
Top disease conditions for ND0612
Top clinical trial sponsors for ND0612
US Patents for ND0612
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| ND0612 | Start Trial | Dopa decarboxylase inhibitor compositions | NeuroDerm, Ltd. (Rehovot, IL) | Start Trial |
| ND0612 | Start Trial | Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a COMT inhibitor and method of administration thereof | LobSor Pharmaceuticals Aktiebolag (Knivsta, SE) | Start Trial |
| ND0612 | Start Trial | Anti-nausea drug combinations | Start Trial | |
| ND0612 | Start Trial | Melt-extruded release controlled pharmaceutical composition and oral dosage form comprising the same | Samyang Biopharmaceutical Corporation (Seoul, KR) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for ND0612
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| ND0612 | Australia | 2015228369 | 2034-03-13 | Start Trial |
| ND0612 | Canada | 2942244 | 2034-03-13 | Start Trial |
| ND0612 | China | 106413754 | 2034-03-13 | Start Trial |
| ND0612 | European Patent Office | 3116475 | 2034-03-13 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
